| Chemical Properties | Back Directory | [density ]
1.470±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 20 mg/ml; DMSO: 10 mg/ml | [form ]
A crystalline solid | [pka]
4.19±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
L-826266 is a EP(1) receptor antagonist. | [Uses]
L-826266 is a selective and competitive EP3 receptor antagonist. L-826266 can be used for convulsive disorders research[1]. | [in vivo]
L-826266 (0.01-1 nmol/site; i.c.v.; once) delays seizures, and increases the latency for clonic and generalized tonic-clonic seizures induced by PTZ[1]. | Animal Model: | Adult male Wistar rats (250-300 g) injected with Pentylenetetrazol (PTZ)[1] | | Dosage: | 0.01 nmol/site, 0.1 nmol/site or 1 nmol/site | | Administration: | i.c.v.; once | | Result: | Increased the latency for clonic and generalized tonic-clonic seizures induced by PTZ. |
| [IC 50]
EP3 | [References]
[1] M S Oliveira, et al. Modulation of pentylenetetrazol-induced seizures by prostaglandin E2 receptors. Neuroscience. 2008 Apr 9;152(4):1110-8. DOI:10.1016/j.neuroscience.2008.01.005
[2] Mauro Schneider Oliveira, et al. Prostaglandin E2 modulates Na+,K+-ATPase activity in rat hippocampus: implications for neurological diseases. J Neurochem. 2009 Apr;109(2):416-26. DOI:10.1111/j.1471-4159.2009.05961.x |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|